Current Report · Items 8.01, 9.01 · 8-K
X4 Pharmaceuticals, Inc.
XFORNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On September 8, 2026, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Company context
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain